MoonLake Immunotherapeutics (MLTX) Misses Q1 EPS by 9c

MoonLake Immunotherapeutics (NASDAQ: MLTX) reported Q1 EPS of ($0.98), $0.09 worse than the analyst estimate of ($0.89).

For earnings history and earnings-related data on MoonLake Immunotherapeutics (MLTX) click here.

You May Also Be Interested In

• Pizza Hut CEO Aaron Powell resigns
• GitLab Inc (GTLB) Tops Q2 EPS by 7c, Beats on Revenue
• Dell Technologies (DELL) Tops Q2 EPS by $2.17, Offers Guidance